WO2026009179 - BIOREACTOR PROCESS DEFINED BY PH AND TEMPERATURE FOR PRODUCING EPTINEZUMAB ANTIBODIES
National phase entry is expected:
Publication Number
WO/2026/009179
Publication Date
08.01.2026
International Application No.
PCT/IB2025/056740
International Filing Date
02.07.2025
Title **
[English]
BIOREACTOR PROCESS DEFINED BY PH AND TEMPERATURE FOR PRODUCING EPTINEZUMAB ANTIBODIES
[French]
PROCÉDÉ DE BIORÉACTEUR DÉFINI PAR PH ET TEMPÉRATURE POUR PRODUIRE DES ANTICORPS D'EPTINÉZUMAB
Applicants **
H. LUNDBECK A/S
Inventors
MCNEILL, Patricia Dianne
SNOW, Kathy
BARNETT, Shaun Douglas
ZIEGLER, Kristin Marie
BENGTSSON, Barbara
Priority Data
63/667,187
03.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2053 | |
| EPO | Filing, Examination, Granting | 8624 | |
| Japan | Filing, Examination, Granting | 2183 | |
| South Korea | Filing, Examination, Granting | 2133 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,733
Contact Us
Abstract[English]
C to 38º C and wherein the pH of about 7 (e.g., between 6.85 and 7.05), e.g., wherein the pH is maintained at about 7 for up to 14 days, or at 6.95. The inventive culturing method controls or enhances the cell growth rate, cell viability, viable cell density and/or antibody titer (Eptinezumab) of the mammalian cells.[French]
L'invention concerne un procédé de culture pour la production d'Eptinézumab dans une culture de cellules de mammifère, comprenant la culture de cellules de mammifère, par exemple, des cellules CHO dans un bioréacteur, par exemple, un bioréacteur à alimentation discontinue, lesdites cellules de mammifère comprenant des séquences d'acide nucléique qui permettent l'expression d'Eptinézumab et la culture étant effectuée à une température comprise entre 33 °C et 38 °C et un pH d'environ 7 (par exemple, entre 6,85 et 7,05), par exemple, le pH étant maintenu à environ 7 pendant jusqu'à 14 jours, ou à 6,95. Le procédé de culture de l'invention contrôle ou améliore le taux de croissance cellulaire, la viabilité cellulaire, la densité de cellules viables et/ou le titre en anticorps (Eptinézumab) des cellules de mammifère.